Peer, C. J., Sissung, T. M., Kim, A., Jain, L., Woo, S., Gardner, E. R., . . . Figg, W. D. (2012). Sorafenib is an Inhibitor of UGT1A1 but is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. Clin Cancer Res.
Stile di citazione ChicagoPeer, Cody J., et al. "Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized By UGT1A9: Implications of Genetic Variants On Pharmacokinetics and Hyperbilirubinemia." Clin Cancer Res 2012.
Citazione MLAPeer, Cody J., et al. "Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized By UGT1A9: Implications of Genetic Variants On Pharmacokinetics and Hyperbilirubinemia." Clin Cancer Res 2012.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.